Physician profile
Dean E Whitley
NPI 1093721037
$9,297.42
in general payments reported to CMS, 2019-2025
27 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,782 · 2022: $1,882 · 2023: $2,044 · 2024: $1,777 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,633.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,316.93 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,156.89 | 2021-2025 | Farxiga, Brilinta, Wainua |
| Boston Scientific Corporation | $1,094.24 | 2022-2025 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $952.52 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $944.40 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $709.93 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $561.94 | 2021-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $504.92 | 2021-2025 | Nexletol |
| Amgen INC. | $434.28 | 2021-2024 | Repatha |
| Pfizer INC. | $257.70 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $217.61 | 2024-2025 | Amvuttra |
| Scpharmaceuticals INC. | $208.94 | 2024-2025 | |
| Novo Nordisk INC | $184.83 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $128.93 | 2023-2024 | Inpefa |
| Medtronic, INC. | $87.67 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $86.27 | 2024-2025 | |
| Abiomed | $73.78 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $73.18 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $68.01 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $60.30 | 2021 | |
| Atricure, INC. | $42.46 | 2025 | Synergy Ablation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.60 | 2021-2025 | Lifevest |
| Glaxosmithkline, LLC. | $25.63 | 2025 | Arexvy, Shingrix |
| Abbott Laboratories | $19.85 | 2025 | Triclip |
| Astellas Pharma US INC | $19.45 | 2021 | |
| Chiesi USA, INC. | $16.10 | 2025 | Kengreal, Cleviprex |
| Inspire Medical Systems, INC. | $15.06 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Whitley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.